Phase II Dose-ranging Study of APD421 in PONV

Postoperative Nausea and Vomiting Clinical Trial

Official title:

Randomised, Double-blind, Placebo-controlled, Dose-ranging Phase II Study of APD421 for the Prevention of Post-operative Nausea and Vomiting

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01510704
• Other study ID #: DP10006
• Status: Completed
• Phase: Phase 2
• Start date: January 2012
• Est. completion date: April 2012

Study information

• Verified date: February 2019
• Source: Acacia Pharma Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess the efficacy and safety of different doses of APD421 in the prevention of post-operative nausea and vomiting (PONV) in adult patients at moderate to high-risk of PONV. Patients must be undergoing elective surgery under general anaesthesia (hysterectomy (any surgical technique), cholecystectomy (any surgical technique) or "other" elective surgery scheduled to last at least one hour from induction of anaesthesia), requiring at least one overnight stay in hospital, and have at least 2 of the following risk factors for PONV: Past history of PONV and/or motion sickness; Non-smoking status; Female gender; Planned opiate use for post-operative analgesia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 215
• Est. completion date: April 2012
• Est. primary completion date: April 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria

1. Male or female patients = 18 years of age

2. Ability and willingness to give written informed consent

3. Patients undergoing elective surgery under general anaesthesia requiring at least one overnight stay in hospital for either:

1. Hysterectomy (any surgical technique)

2. Cholecystectomy (any surgical technique)

3. Other elective surgery requiring overnight admission to hospital and scheduled to last at least 1 hour from induction of anaesthesia

4. Patients with at least 2 of the following risk factors for PONV:

1. Past history of PONV and/or motion sickness

2. Habitual non-smoking status

3. Female sex

4. Expected to receive opioid analgesia post-operatively

5. American Society of Anesthesiologists (ASA) risk score I-III

6. Adequate cardiac, hepatic and renal function

• QTc interval < 500 ms

• Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) < 5 x upper limit normal (ULN)

• Bilirubin < 3 x ULN

• Creatinine < 2 x ULN

7. Adequate haematological function

• Haemoglobin = 9 g/dL

• White blood count = 3.0 x 109/L

• Platelet count = 100 x 109/L

8. For females of child-bearing potential: ability and willingness to use a highly effective form of contraception (e.g., abstinence from sexual intercourse, surgical sterilisation (of subject or partner) or a double-barrier method of contraception such as either an intra-uterine device (IUD) or an occlusive cap with spermicide, in conjunction with partner's use of a condom) between the date of screening and at least 48 hours after administration of study drug.

Exclusion Criteria

1. Patients undergoing outpatient/day case surgery

2. Patients undergoing surgery where the patient is expected to remain ventilated for a period after surgery

3. Patients undergoing intra-thoracic, transplant or central nervous system surgery

4. Patients receiving a local anaesthetic/regional neuraxial (intrathecal or epidural) block

5. Patients who are expected to need a naso- or oral-gastric tube in situ after surgery is completed

6. Patients receiving the active ingredient of APD421 for any indication within the last 2 weeks

7. Patients who are allergic to the active ingredient or any of the excipients of APD421

8. Patients with a pre-existing vestibular disorder or history of dizziness

9. Patients with pre-existing nausea or vomiting in the 24 hours before surgery

10. Patients treated with regular anti-emetic therapy including corticosteroids

11. Patients being treated with medications which could induce torsades de pointes, including Class Ia antiarrhythmic agents such as quinidine, disopyramide, procainamide; Class III antiarrhythmic agents such as amiodarone and sotalol; and other medications such as bepridil, cisapride, thioridazine, methadone, IV erythromycin, IV vincamine, halofantrine, pentamidine, sparfloxacin

12. Patients being treated with levodopa

13. Patients who are pregnant or breast feeding

14. Patients with a history of alcohol abuse

15. Patients with pre-existing, clinically significant cardiac arrhythmia

16. Patients diagnosed with Parkinson's disease

17. Patients who have received anti-cancer chemotherapy in the previous 4 weeks

18. Patients with a history of epilepsy

19. Any other concurrent disease or illness that, in the opinion of the investigator makes the patient unsuitable for the study

20. Patients who have participated in a previous study within the last 28 days (French sites only: Patients who have participated in a previous study within the last 6 months, if required by national or local regulations)

Related Conditions & MeSH terms

• Nausea
• Postoperative Nausea and Vomiting
• Vomiting

Intervention

Drug:
• APD421
IV
• Placebo
IV

Locations

Country	Name	City	State
France	University Hospital	Besançon
France	Hôpital mère enfant	Bron
France	Hôpital Huriez	Lille
France	University Hospital	Nancy
France	Hôpital FOCH	Paris
France	Hautepierre Hospital	Strasbourg
Germany	HELIOS Klinikum Aue	Aue
Germany	Charité - Universitätsmedizin	Berlin
Germany	Universität Heidelberg	Heidelberg
Germany	Klinikum Ludwigshafen	Ludwigshafen
Germany	Philipps University	Marburg
Germany	University Hospitals of Würzburg	Würzburg
United States	Duke University Medical Center	Durham	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Acacia Pharma Ltd

Countries where clinical trial is conducted

United States,  France,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Post-operative Nausea or Vomiting		24 hours